Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ANGLE plc ( (GB:CLBX) ) just unveiled an announcement.
CelLBxHealth plc has strengthened its board with the immediate appointment of Peter Collins as chief executive officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart as non-executive directors, while non-executive director Joseph Eid will step down at the end of January 2026. Executive chair Jan Groen said the expanded board brings additional life sciences and strategic expertise as the company targets new strategic opportunities and seeks to enhance long-term shareholder value, underlining a governance and leadership refresh at a key stage in the commercial rollout of its Parsortix CTC platform and related services.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc, listed on AIM as CLBX, is a circulating tumour cell (CTC) intelligence company providing innovative CTC-based solutions for research, drug development and clinical oncology. Its patent-protected Parsortix platform isolates CTCs from blood and integrates with existing laboratory instruments to enable downstream whole-cell imaging, proteomic profiling and genomic workflows. The company generates revenue through product sales of the Parsortix system and consumables, laboratory services for clinical-trial support and assay development, and lab-developed tests backed by strategic partnerships, with services delivered from its GCLP-certified UK laboratory.
Average Trading Volume: 3,069,214
Technical Sentiment Signal: Sell
Current Market Cap: £11.93M
Find detailed analytics on CLBX stock on TipRanks’ Stock Analysis page.